The non-profit German Institute for Cell and Tissue Replacement (DIZG) is a pharmaceutical manufacturer based in Berlin and is one of the largest pharmaceutical and biotechnological non-profit organizations of its kind in Europe.
Optimizing transplant properties, adapting them to ever-changing clinical requirements, identifying new surgical applications for existing transplant types, and developing new transplants are what drive the Research & Development (R&D) team.
In Germany, human cell and tissue transplants of human origin are regulated as medicinal products and/or require approval. This means that their production, biological safety, and clinical application are subject to oversight by German authorities. In DIZG's cleanrooms, all regulatory requirements are strictly followed.
The DIZG is investing in a new production facility for allogeneic devitalized tissue preparations to ensure safe patient care. From the groundbreaking in 2021 to the topping-out ceremony and beyond – discover the progress here.
The tissue donations received by the DIZG originate from a living person or are collected post-mortem, i.e. after death. Under sections 3 and 4 of the German Transplantation Act, tissue removal, like organ removal, is only permitted with the consent of the donor or the relatives of the deceased.
The Tissue Donation department works closely with national and international collection facilities as well as with clinics that participate in living donation programmes. Together they ensure that human transplants are available for upcoming operations.
Bone and soft tissue can be donated after death, i.e. post-mortem. However, according to the provisions of the Transplantation Act § 3 and § 4, the removal of tissue is only permitted with the donor's consent.
The demand for safe human tissue transplants exceeds the supply. The more clinics participate in the DIZG donation programme, the more patients can be supplied with human transplants throughout Germany and Europe. This is why it makes sense to expand the tissue donation programme across the board.
Since its foundation, around 868,000 transplants have been manufactured infection-free.
We support doctors* and surgeons in their day-to-day clinical challenges with our versatile human allografts in form of tendons, menisci, bones and much more.
Since its foundation, around 933,000 transplants have been manufactured infection-free.
The DIZG's transplant portfolio already includes 230 innovative human transplant forms for widespread clinical provision. Discover our comprehensive range!
Autologous keratinocyte transplants are often an indispensable treatment method for extensive skin wounds and severe grade 2b and 3 burns. For more than 20 years, the DIZG has been the only institution in Germany to produce these in the form of sheets of human keratinocytes and a suspension of human keratinocytes.
Our autologous cell cultures are produced to the highest standards in the highest possible cleanroom class A. The cultivation and provision of keratinocytes are subject to strict regulatory requirements, which require the DIZG to maintain a separate cleanroom area just for them.
We offer you a comprehensive service for our autologous cell cultures, starting long before the transplantation. We also assist burn clinics in meeting regulatory requirements.
